KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Average (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Equity Average for 15 consecutive years, with $183.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Average rose 264.63% year-over-year to $183.0 million, compared with a TTM value of $183.0 million through Jun 2025, up 264.63%, and an annual FY2024 reading of -$76.8 million, up 59.47% over the prior year.
  • Equity Average was $183.0 million for Q2 2025 at Alnylam Pharmaceuticals, up from $91.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $971.2 million in Q1 2021 and bottomed at -$333.7 million in Q2 2023.
  • Average Equity Average over 5 years is $169.3 million, with a median of $52.0 million recorded in 2022.
  • The sharpest move saw Equity Average tumbled 629.51% in 2023, then soared 264.63% in 2025.
  • Year by year, Equity Average stood at $672.0 million in 2021, then tumbled by 116.8% to -$112.9 million in 2022, then crashed by 71.13% to -$193.3 million in 2023, then surged by 125.73% to $49.7 million in 2024, then skyrocketed by 268.08% to $183.0 million in 2025.
  • Business Quant data shows Equity Average for ALNY at $183.0 million in Q2 2025, $91.3 million in Q1 2025, and $49.7 million in Q4 2024.